Lactobacillus casei M2b and application thereof

Abstract

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus casei M2b and application thereof.The lactobacillus casei M2b is preserved in the China Center for Type Culture Collection with the preservation number of CCTCC NO: M20221748, the lactobacillus casei M2b can remarkably reduce the blood uric acid level and the whole-body inflammation level of mice at the same time, liver and kidney injuries caused by hyperuricemia can be relieved, and the lactobacillus casei M2b has the advantages that the lactobacillus casei M2b can be used for preventing and treating hyperuricemia; the strain can be used for improving intestinal flora disorder of mice with hyperuricemia, can be used for preparing functional microbial agents or medicines for preventing or relieving hyperuricemia and related symptoms thereof, and has a wide application prospect.

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a Lactobacillus casei M2b and an application thereof. Background Art

[0002] Uric acid is the final product of purine metabolism in the human body. Disorders in purine metabolism or uric acid excretion may cause an increase in the concentration of serum uric acid in the human body, leading to hyperuricemia. Long-term hyperuricemia causes uric acid to precipitate in the form of crystals and deposit in the joints, inducing gout. With the improvement of people's living standards, the types and quantities of high-purine and high-protein diets in the diet structure have gradually increased, as well as changes in lifestyle, the risk of hyperuricemia and gout has continued to increase, showing a clear upward and younger trend in recent years. Hyperuricemia and gout are independent risk factors for diseases such as chronic kidney disease, hypertension, cardiovascular and cerebrovascular diseases and diabetes, and have become one of the world's increasingly serious major public health problems.

[0003] Currently, the main drugs for the treatment of hyperuricemia include febuxostat (inhibits uric acid production), benzbromarone (a drug that promotes uric acid excretion), etc. However, side effects such as allergies, nausea and vomiting, and liver and kidney involvement are common. Drug treatment for asymptomatic hyperuricemia is still controversial worldwide. Therefore, the development of new drugs that are safe, effective, and have no side effects is the current research hotspot for alleviating hyperuricemia.

[0004] Studies have shown that hyperuricemia is closely related to intestinal flora imbalance. The diversity of intestinal flora in patients with hyperuricemia decreases, the number of conditional pathogens such as Escherichia coli, Bacteroides and Anaerobic bacteria increases, and the number of beneficial bacteria such as Lactobacillus and Bifidobacterium decreases. There is an obvious imbalance. Regulating intestinal flora and uric acid metabolism by supplementing probiotics has become a new treatment method to alleviate hyperuricemia. Although there are patents on strains with the function of lowering blood uric acid, such as Lactobacillus rhamnosus fmb14 Lactobacillus casei M2b, disclosed in publication number CN114574382A, entitled Lactobacillus rhamnosus fmb14 with the function of preventing or alleviating hyperuricemia and its application; Lactobacillus plantarum FS4722, disclosed in publication number CN114507621A, entitled A strain of Lactobacillus plantarum and its application in lowering uric acid, reducing weight and anti-inflammation; Lactobacillus gasseri CCFM1133, disclosed in publication number CN12458027A, entitled A strain of Lactobacillus gasseri and its use in alleviating and treating hyperuricemia, due to the source and properties of the strains, their degradation characteristics and application effects are also different. Currently, the disclosed patents on probiotics that can prevent or alleviate hyperuricemia are still very limited. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a Lactobacillus casei M2b and application thereof.

[0006] The first object of the present invention is to provide a strain of Lacticaseibacillus sp. M2b, which has been deposited in China Center for Type Culture Collection, address: Luojia Mountain, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and its deposit number is CCTCC NO: M20221748.

[0007] Lactobacillus casei M2b has the following biological characteristics:

[0008] (1) Colony characteristics: The colonies are white, round, moist, opaque, and have neat edges.

[0009] (2) Bacterial characteristics: The bacteria are rod-shaped, 0.4-0.6μm×0.8-1.6μm, arranged singly or in pairs, and Gram-positive.

[0010] (3) Growth characteristics: 0-3h is the lag phase, 3-16h is the logarithmic growth phase, 16-20h is the stable phase, and after 21h it enters the decline phase.

[0011] The second object of the present invention is to provide a complex containing the Lactobacillus casei M2b.

[0012] The number of Lactobacillus casei M2b is ≤1.0×10 10 CFU / mL or ≤1.0×10 10 CFU / g.

[0013] Preferably, the complex is a bacterial agent, and the bacterial agent contains the Lactobacillus casei M2b as an active ingredient.

[0014] Preferably, in the bacterial agent, the concentration of the Lactobacillus casei M2b strain is 1.0×10 9 ~1.0×10 10 CFU / g.

[0015] Preferably, the complex is a medicine, a food additive, a biological functional bacterial agent, or a functional food.

[0016] Preferably, the complex contains a live strain, a lyophilized powder, an inactivated strain or a strain metabolite of Lactobacillus casei M2b.

[0017] Preferably, the drug contains a pharmaceutically acceptable carrier.

[0018] Preferably, the pharmaceutically acceptable carrier is one or more of a binder, a wetting agent, a filler or a disintegrant.

[0019] Preferably, the binder is one or more of starch slurry, syrup, maltose or refined honey; the wetting agent is one or more of glycerol, propylene glycol, polyethylene glycol, magnesium stearate, sodium stearyl fumarate or silicon dioxide; the filler is one or more of starch, dextrin, microcrystalline cellulose or mannitol; the disintegrant is one or more of sodium carboxymethyl starch, low-substituted cellulose, cross-linked sodium carboxymethyl cellulose or cross-linked polyvinyl pyrrolidone;

[0020] The present invention also claims to protect the use of Lactobacillus casei M2b in preparing fermented food.

[0021] Preferably, the application includes but is not limited to using Lactobacillus casei M2b as a fermentation microorganism to ferment food raw materials.

[0022] The third object of the present invention is to provide the use of the Lactobacillus casei M2b in preparing a product for preventing or alleviating hyperuricemia.

[0023] Preferably, the Lactobacillus casei M2b is used to prepare a product that degrades uric acid in vitro.

[0024] Preferably, the Lactobacillus casei M2b is used to prepare a product for reducing inflammation caused by hyperuricemia.

[0025] Preferably, the Lactobacillus casei M2b is used to prepare a product for alleviating liver and kidney damage caused by hyperuricemia.

[0026] Preferably, the Lactobacillus casei M2b is used to prepare a product for preventing or alleviating intestinal flora disturbance caused by hyperuricemia.

[0027] Preferably, the product is a bacterial solution of Lactobacillus casei M2b; preferably, the concentration of Lactobacillus casei M2b in the bacterial solution is 1.0×10 9 ~1.0×10 10 CFU / g;

[0028] The Lactobacillus casei M2b increases the abundance of Muribaculaceae_unclassified and reduces the abundance of Akkermansia in the intestine.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] When used, the Lactobacillus casei M2b of the present invention can effectively reduce the serum uric acid level of mice, reduce the inflammation level, alleviate liver and kidney damage, and regulate intestinal flora disorder, with significant effects.

[0031] (1) The degradation rate of Lactobacillus casei M2b provided by the present invention reached 62.11% after continuous culture for 7 days in MRS culture medium containing 6400 μmol / L uric acid.

[0032] (2) The Lactobacillus casei M2b bacterial liquid provided by the present invention has a simple preparation process and has the advantages of convenient preparation and high safety.

[0033] (3) After the Lactobacillus casei M2b bacterial solution provided by the present invention intervened in the hyperuricemia model mice, the average serum uric acid level of the intervention group mice was significantly lower than that of the model group mice, indicating that the Lactobacillus casei M2b bacterial solution of the present invention has a significant uric acid-lowering effect and effectively prevents the occurrence of hyperuricemia. The Lactobacillus casei M2b can be used to prepare a drug for preventing or alleviating hyperuricemia.

[0034] (4) After the Lactobacillus casei M2b bacterial solution provided by the present invention was used to intervene in hyperuricemia model mice, the serum inflammatory factors IL-1β and IL-6 of the intervention group mice were significantly reduced. The Lactobacillus casei M2b can be used to reduce inflammation caused by hyperuricemia.

[0035] (5) After the Lactobacillus casei M2b bacterial solution provided by the present invention intervened in hyperuricemia model mice, the serum creatinine (Cre) level of the intervention group mice decreased, and the activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) decreased. The Lactobacillus casei M2b can be used to alleviate liver and kidney damage caused by hyperuricemia.

[0036] (6) The lactobacillus casei M2b bacterial liquid provided by the present invention alleviates the intestinal flora disorder in hyperuricemia mice. At the genus level, compared with the normal group, the abundance of Muribaculaceae_unclassified decreased in the model group and increased in Akkermansia. After the intervention of lactobacillus casei M2b, the intestinal flora composition recovered to be similar to that of the control group, and the beneficial bacteria Lacticaseibacillus increased and the pathogenic bacteria Erysipelatoclostridium decreased. The lactobacillus casei M2b can improve the intestinal microecological system and is applied in alleviating the intestinal flora disorder caused by hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is a plate culture photo of Lactobacillus casei M2b (10×100);

[0038] Figure 2 The microscopic examination results of Gram staining of Lactobacillus casei M2b (10×100);

[0039] Figure 3The changes of serum uric acid levels in each group of mice; Control is the control group, HUA is the hyperuricemia model group, ALL is the allopurinol intervention group, and M2b is the Lactobacillus casei M2b intervention group; *** is compared with the control group, P<0.001, # is compared with the model group, P<0.05, and ### is compared with the model group, P<0.001;

[0040] Figure 4 is the level of serum inflammatory factors in each group of mice, where A is IL-1β and B is IL-6;

[0041] Figure 5 The enzyme activity levels of aspartate aminotransferase (A) and alanine aminotransferase (B) in each group of mice;

[0042] Figure 6 is the serum creatinine level of mice in each group;

[0043] Figure 7 This is the α-diversity analysis of the intestinal flora of each group of mice, where A is the Chao1 index and B is the Shannon index;

[0044] Figure 8 β-diversity analysis of intestinal flora in each group of mice;

[0045] Fig. 9 It is a bar graph of relative abundance of species at the genus level in each group of mice. The arrows in the figure indicate the order of relative abundance of species. DETAILED DESCRIPTION

[0046] The specific embodiments of the present invention are described in detail below, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention. The experimental methods described in the embodiments of the present invention are conventional methods unless otherwise specified.

[0047] Example 1

[0048] Isolation, Screening and Identification of Lactobacillus casei M2b

[0049] (I) Isolation and screening of human uric acid-degrading bacteria

[0050] (1) Stool sample collection

[0051] Healthy male population was screened according to the inclusion and exclusion criteria, and the fasting morning stool of the research subjects was collected using an intestinal microbial sample collection kit, stored in an ice box, and returned to the laboratory within 2 hours.

[0052] A. Inclusion criteria: No major illness within three months before the sampling period, no antibiotics, and normal uric acid level (between 190-417 μmol / L).

[0053] B. Exclusion criteria:

[0054] (A) Eliminate factors that may affect changes in intestinal flora, such as gastrointestinal diseases and metabolic diseases;

[0055] (B) Long-term use of diuretics, high-dose glucocorticoids, anti-tuberculosis drug pyrazinamide, sulfonamide and quinolone antibiotics, uric acid-lowering drugs such as benzbromarone and probenecid, allopurinol, sodium bicarbonate, angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB);

[0056] (C) Urinary tract stones, renal insufficiency;

[0057] (D) Hereditary enzyme deficiency, congenital deficiency of xanthine oxidase and purine nucleotidase;

[0058] (E) Myocardial infarction, acute heart failure, acute respiratory failure, severe lung disease, abnormal thyroid function, liver function and rheumatism and immune diseases; gout, various blood diseases, malignant tumors, rhabdomyolysis, acute and chronic infections, etc.;

[0059] (F) Chronic lead poisoning, chronic cadmium poisoning, and long-term fasting;

[0060] (G) Hypermobility and epileptic status;

[0061] (2) Preparation of uric acid selective medium

[0062] Different concentrations of uric acid solution were added to MRS solid medium (containing peptone 10g / L, beef extract powder 8g / L, yeast extract powder 4g / L, glucose 20g / L, dipotassium hydrogen phosphate 2g / L, diammonium hydrogen citrate 2g / L, sodium acetate 5g / L, magnesium sulfate 0.2g / L, manganese sulfate 0.04g / L, Tween 801g / L, agar 20g / L, pH 5.7±0.2), and the liquid and solid culture media were prepared after constant volume and autoclaved for standby use. The concentration of uric acid culture medium was set to 8 gradients of 50μmol / L, 100μmol / L, 200μmol / L, 400μmol / L, 800μmol / L, 1600μmol / L, 3200μmol / L, and 6400μmol / L.

[0063] Compared with MRS solid medium, MRS liquid medium does not contain agar, but other components are the same.

[0064] (3) Isolation and identification of human uric acid-degrading bacteria

[0065] Use a sterile loop to quickly pick pretreated fresh feces 1-2g into MRS liquid culture medium containing different concentrations of uric acid. Respectively, culture in a 37°C constant temperature incubator under anaerobic conditions for 36-48h, and culture for 40 hours in the present embodiment. The next day, the culture in the MRS liquid culture medium cultured with different concentration gradients was transferred to the MRS solid culture medium by the partition line method, observed after 24h, and the single bacterium colony obtained by picking and separating was transferred to 6400μmol / L high concentration uric acid MRS solid culture medium for domestication. The colony partitions of different forms after domestication were marked with 6400μmol / L high concentration uric acid MRS solid culture medium, and continuous separation and purification were performed three times until a pure single bacterium colony was isolated and purified, and the single bacterium colony obtained was numbered M2b.

[0066] like Figure 1 As shown, the colonies of the strain M2b on the modified MRS fixed plate are white, round, moist, opaque, and have neat edges; Gram staining of the screened strains is shown in Figure 2 As shown, the strain is a Gram-positive bacterium, which is rod-shaped, arranged singly or in pairs, and has no spores. A single colony that has been purified and cultured for 48 hours on the separation medium is picked up with an inoculation loop and placed in a 20% glycerol preservation solution, vortexed for 30 seconds to mix, and stored at -80°C.

[0067] (II) Identification of human uric acid-degrading bacteria

[0068] (1) Biochemical identification

[0069] The fresh culture of M2b was made into 0.5 McLaren unit bacterial solution and added into VITEKANC identification card for identification using BioMerieux (France). The identification results are listed in Table 1. The biochemical identification result was Lactobacillus casei.

[0070] Table 1 Identification results of Lactobacillus casei M2b VITEKANC

[0071]

[0072] Note: “+” means positive, “w” means weak positive, and “-” means negative

[0073] (2) Molecular Biological Identification

[0074] The screened strain M2b was cultured for 24 hours, 1 mL of the bacterial solution was taken into a 1.5 mL centrifuge tube, and the bacterial genome was extracted (according to the operating procedures of TIANGEN Rapid Bacterial Genomic DNA Isolation Kit)).

[0075] T The sequence similarity was 100%. The biochemical identification was consistent with the molecular biological identification, and it was named Lactobacillus casei M2b. It was stored at -80℃ for future use.

[0076] The screened strain M2b was deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20221748.

[0077] Example 2

[0078] Uric acid degradation ability of Lactobacillus casei M2b in vitro

[0079] The components of the MRS solid medium and the MRS liquid medium are the same as those in Example 1.

[0080] (1) Lactobacillus casei M2b was streaked onto MRS solid medium and cultured at 37°C for 36 h. In this embodiment, a single colony was selected and inoculated into MRS liquid medium for activation for 24 h. The colony was then re-inoculated into 5 mL of new MRS liquid medium at a 1% inoculum amount and cultured at 37°C for 48 h. The bacterial cell concentration was adjusted to 1×10 9 CFU / mL is reserved.

[0081] (2) The cells were inoculated at a 1% inoculum into MRS liquid culture medium with a final concentration of 6400 μmol / L. The filtrate was taken and the uric acid concentration was measured using the uricase colorimetric method after 1, 3, 5, and 7 days of culture. The degradation efficiency was calculated as [(original uric acid concentration - concentration after degradation) / original uric acid concentration] × 100%.

[0082] Table 2 Efficiency of Lactobacillus casei M2b in vitro degradation of uric acid

[0083]

[0084] Example 3

[0085] Effect of Lactobacillus casei M2b on serum uric acid in hyperuricemic mice

[0086] The animal experiment used healthy male Balb / c mice of standard body weight (24-32g) aged 6-8 weeks and free of specific pathogens. After one week of adaptive feeding, they were randomly divided into 4 groups, 6 mice in each group, namely control group, model group, M2b group, and allopurinol group. During the experiment, the mice's food and water intake were not restricted by any factors.

[0087] The experimental setup is as follows:

[0088] Control group (Control): gavage 0.3 mL of normal saline twice a day, with an interval of 1 hour between each gavage;

[0089] Model group (Hyperuricemia, HUA): 300 mg / kg hypoxanthine and 500 mg / kg potassium oxonate were administered intragastrically every day, followed by 0.3 mL normal saline 1 hour later, for 14 consecutive days;

[0090] M2b group (M2b): 300 mg / kg hypoxanthine and 500 mg / kg potassium oxonate were administered intragastrically every day, and 0.3 mL of Lactobacillus casei M2b bacterial solution was administered intragastrically 1 hour later. The bacterial concentration in the bacterial solution was 1.0×10 9 CFU / mL, 14 consecutive days;

[0091] Allopurinol group (ALL): 300 mg / kg hypoxanthine and 500 mg / kg potassium oxonate were administered intragastrically every day, followed by 5 mg / kg allopurinol 1 hour later for 14 consecutive days.

[0092] After the experiment, blood samples were collected from mice by eyeball blood sampling, and serum was collected by centrifugation at 3000 rpm / min for 10 min. Serum uric acid levels were tested according to the kit method established in Nanjing. The test results are shown in Figure 3 As shown, compared with the model group, the serum uric acid concentration of the mice in the Lactobacillus casei M2b group decreased from 264.7 μmol / L to 179.7 μmol / L, a decrease of 32.1%, indicating that the Lactobacillus casei M2b of the present invention has the function of alleviating hyperuricemia.

[0093] Example 4

[0094] Lactobacillus casei M2b reduces serum pro-inflammatory cytokines in hyperuricemia mice

[0095] The experimental animal grouping and experimental settings were the same as in Example 3. The detection of serum inflammatory factors interleukin 1β (IL-1β) and interleukin 6 (IL-6) was carried out according to the method of Wuhan Gene Midea's kit. The results are as follows Figure 4 As shown. After Lactobacillus casei M2b intervened in hyperuricemia mice, the levels of serum inflammatory factors in mice decreased significantly. The levels of IL-1β and IL-6 in the serum of mice in the normal group were 208.3 and 190.0 pg / mL, while the concentrations of inflammatory factors in the serum of mice in the model group increased to 224.0 and 198.6 pg / mL. Hyperuricemia led to enhanced inflammatory response in mice, while the levels of serum inflammatory factors IL-1β and IL-6 in the Lactobacillus casei M2b group mice decreased to 82.5 and 160.4 pg / mL, respectively, which were 63.2% and 31.1% lower than those in the model group.

[0096] The Lactobacillus casei M2b provided by the present invention can alleviate low-grade systemic inflammation caused by hyperuricemia, and can be used in reducing inflammation caused by hyperuricemia.

[0097] Example 5

[0098] Lactobacillus casei M2b reduces serum creatinine levels in hyperuricemic mice

[0099] The experimental animal grouping and experimental setting were the same as in Example 3. The detection of serum creatinine was carried out according to the method of the kit established in Nanjing. The results are shown in Figure 5 After Lactobacillus casei M2b intervened in hyperuricemia mice, the creatinine level of the mice decreased significantly. The creatinine content in the serum of the normal group mice was 10.6μmol / L, while the creatinine concentration of the model group mice increased to 27.8μmol / L. Hyperuricemia caused renal function damage in mice, while the creatinine content of the Lactobacillus casei M2b group mice decreased to 9.6μmol / L, a decrease of 65.5% compared with the model group.

[0100] The Lactobacillus casei M2b provided by the present invention can alleviate renal damage caused by hyperuricemia, and can be used in alleviating renal damage caused by hyperuricemia.

[0101] Example 6

[0102] Lactobacillus casei M2b downregulates serum aspartate aminotransferase and alanine aminotransferase activities in hyperuricemia mice

[0103] The experimental animal grouping and experimental setting were the same as in Example 3. The detection of serum creatinine was carried out according to the method of the kit established in Nanjing. The results are shown in Figure 6 The activities of AST and ALT in the serum of mice in the normal group were 113.5 and 130.0 U / L, while those in the model group increased to 135.5 and 178.0 U / L. Hyperuricemia caused liver damage in mice, while the activities of AST and ALT in the Lactobacillus casei M2b group decreased to 97.7 and 148.2 U / L, respectively, which were 27.9% and 16.7% lower than those in the model group.

[0104] The Lactobacillus casei M2b provided by the present invention can alleviate liver damage caused by hyperuricemia, and can be used in alleviating liver damage caused by hyperuricemia.

[0105] Example 7

[0106] Regulatory effect of Lactobacillus casei M2b on intestinal flora in hyperuricemia mice

[0107] The experimental animal grouping and experimental settings were the same as in Example 3. 0.1 g of mouse colon contents were collected and sent to Hangzhou Lianchuan Biotechnology Co., Ltd., and the full-length 16Sr DNA in the mouse fecal genome was sequenced using Illunima MiSeq. The bacterial community composition and group abundance were counted using the QIIME platform, and the community α and β diversity indices were calculated.

[0108] α-diversity analysis found that the species diversity of the model group was lower than that of the normal control group and the Lactobacillus casei M2b intervention group. The intestinal microbial diversity of the allopurinol intervention group was lower than that of the model group. This shows that Lactobacillus casei M2b increased the diversity of intestinal microbial communities, but the allopurinol intervention group did not significantly improve the species diversity of intestinal flora. Figure 7 As shown. β diversity using principal coordinates analysis (PCoA) found that the intestinal flora of the four groups of mice were significantly different. The discrete degree of the sample point distribution can reflect that the composition of the intestinal flora of the control group, the model group and the allopurinol group can be clearly distinguished. There are differences in the distribution area of ​​the intestinal flora of the Lactobacillus casei M2b group and the model group, but there is no obvious difference in the distribution area of ​​the intestinal flora between the model group and the allopurinol group. The results are shown in Figure 8 shown.

[0109] The Lactobacillus casei M2b provided by the present invention can improve the intestinal flora imbalance caused by hyperuricemia, and can be used in alleviating the intestinal flora disorder caused by hyperuricemia.

[0110] The dominant phyla of the intestinal flora of each group of mice at the phylum level were Verrucomicrobia, Bacteroidetes, Firmicutes, and Proteobacteria. However, the community composition of each group of mice at the genus level was quite different, such as Fig. 9 As shown. The abundance of Muribaculaceae_unclassified in the model group was 17.94%, which was significantly decreased compared with the abundance of 27.45% in the control group, while the abundance of Muribaculaceae_unclassified in the Lactobacillus casei M2b group recovered to 25.53%. The abundance of Akkermansia in the control group was 11.94%, while the abundance of Akkermansia in the model group increased by 44.63%, and the abundance of Akkermansia in the Lactobacillus casei M2b intervention group decreased to 39.51%. In addition, the abundance of the beneficial bacteria Lactobacillus was 8.76% in the control group, and there was no Ligilactobacillus in the model group. The abundance of the pathogenic bacteria Erysipelatoclostridium was 1.69%, becoming one of the more abundant genera in the model group. The abundance of Lacticaseibacillus in the M2b group was 2.02%, and its intestinal flora composition was similar to that of the control group.

[0111] The Lactobacillus casei M2b intervention provided by the present invention has a significant regulatory effect on the genus-level disorder in the intestinal flora caused by hyperuricemia.

[0112] It should be noted that when the claims of the present invention involve numerical ranges, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.

[0113] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0114] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A Lactobacillus casei M2b, characterized in that It has been deposited in China Center for Type Culture Collection with the deposit number CCTCC NO: M20221748.

2. A bacterial agent, characterized in that The bacterial agent uses the Lactobacillus casei M2b described in claim 1 as an active ingredient.

3. The bacterial agent according to claim 2, characterized in that The concentration of Lactobacillus casei M2b in the bacterial agent is 1.0×10 9 ~1.0×10 10 CFU / g.

4. A product for preventing or alleviating hyperuricemia prepared by the Lactobacillus casei M2b according to claim 1.

5. Use of Lactobacillus casei M2b according to claim 1 in preparing a product for preventing or alleviating hyperuricemia.

6. The use according to claim 5, characterized in that: The Lactobacillus casei M2b is used for preparing a product for degrading uric acid in vitro.

7. The use according to claim 5, characterized in that: The Lactobacillus casei M2b is used for preparing a product for reducing inflammation caused by hyperuricemia.

8. The use according to claim 5, characterized in that: The Lactobacillus casei M2b is used for preparing a product for alleviating liver and kidney damage caused by hyperuricemia.

9. The use according to claim 5, characterized in that: The Lactobacillus casei M2b is used for preparing a product for preventing or alleviating intestinal flora disorder caused by hyperuricemia.

10. The use according to claim 9, characterized in that: The product is a bacterial liquid of Lactobacillus casei M2b; The Lactobacillus casei M2b increases the abundance of Muribaculaceae_unclassified and reduces the abundance of Akkermansia in the intestine.

Images